SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-17-018672
Filing Date
2017-09-14
Accepted
2017-09-14 16:26:18
Documents
37
Period of Report
2017-07-31

Document Format Files

Seq Description Document Type Size
1 10-Q kalv-10q_20170731.htm 10-Q 616959
2 EX-31.1 kalv-ex311_296.htm EX-31.1 13624
3 EX-31.2 kalv-ex312_297.htm EX-31.2 12978
4 EX-32.1 kalv-ex321_298.htm EX-32.1 11924
  Complete submission text file 0001564590-17-018672.txt   1943226

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT kalv-20170731.xml EX-101.INS 289861
6 XBRL TAXONOMY EXTENSION SCHEMA kalv-20170731.xsd EX-101.SCH 21324
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE kalv-20170731_cal.xml EX-101.CAL 29248
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE kalv-20170731_def.xml EX-101.DEF 29075
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20170731_lab.xml EX-101.LAB 137828
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20170731_pre.xml EX-101.PRE 97535
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-36830 | Film No.: 171085904
SIC: 2834 Pharmaceutical Preparations